therapeutic cheat sheet

The Wound Healing Response Therapeutic Cheat Sheet
wound healing
by Michael J. Visconti, DO | Emily R. Davis, DO on
Following numerous office-based dermatologic procedures, erythema, swelling, and scarring are often feared complications experienced by our patients. Understanding the wound healing response is synonymous with understanding the stages of healing and ultimately the clinical appearance of each wound. Possessing and sharing a firm grasp on this knowledge allows for patient empowerment during the woun …
Dermabrasion Therapeutic Cheat Sheet
by Michael J. Visconti, DO | Emily R. Davis, DO on
At its core, dermabrasion is the application of an abrasive surface to the skin with the goal of inciting cutaneous injury to subsequently induce a healing response. This relationship is utilized in dermabrasion to promote improved complexion, contour, and appearance of the skin in the treatment of acne scarring, surgical scarring, destruction of benign cutaneous lesions, as well as a secondary re …
Rituximab Therapeutic Cheat Sheet
by Emily Murphy, MD on
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other …
Baricitinib Therapeutic Cheat Sheet
by Alexis Carrington, MD on
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l …
Roflumilast Therapeutic Cheat Sheet
by Adam Rosenfeld, MD on
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o …